| 1282 | Humans (MeSH) |
| 1029 | Pandemics (MeSH) |
| 783 | Betacoronavirus (MeSH) |
| 526 | Coronavirus Infections (epidemiology) |
| 524 | Pneumonia, Viral (epidemiology) |
| 327 | Female (MeSH) |
| 295 | Male (MeSH) |
| 265 | Coronavirus Infections (complications) |
| 264 | Pneumonia, Viral (complications) |
| 225 | Middle Aged (MeSH) |
| 224 | Pneumonia, Viral (MeSH) |
| 223 | Pandemics (prevention & control) |
| 222 | Coronavirus Infections (prevention & control) |
| 220 | Coronavirus Infections (diagnosis) |
| 217 | Pneumonia, Viral (prevention & control) |
| 216 | Coronavirus Infections (MeSH) |
| 210 | Aged (MeSH) |
| 201 | Pneumonia, Viral (diagnosis) |
| 194 | Coronavirus Infections (virology) |
| 193 | Pneumonia, Viral (virology) |
| 177 | Coronavirus Infections (drug therapy) |
| 164 | Pneumonia, Viral (therapy) |
| 164 | Coronavirus Infections (therapy) |
| 164 | Adult (MeSH) |
| 156 | Pneumonia, Viral (drug therapy) |
| 138 | France (epidemiology) |
| 137 | Pneumonia, Viral (transmission) |
| 137 | Coronavirus Infections (transmission) |
| 118 | Betacoronavirus (isolation & purification) |
| 89 | Aged, 80 and over (MeSH) |
| 88 | Coronavirus Infections (immunology) |
| 87 | Pneumonia, Viral (immunology) |
| 81 | France (MeSH) |
| 76 | Risk Factors (MeSH) |
| 73 | Retrospective Studies (MeSH) |
| 73 | Child (MeSH) |
| 68 | Practice Guidelines as Topic (MeSH) |
| 67 | Pneumonia, Viral (mortality) |
| 67 | Coronavirus Infections (mortality) |
| 67 | Betacoronavirus (pathogenicity) |
| 65 | Antiviral Agents (therapeutic use) |
| 61 | Animals (MeSH) |
| 60 | Betacoronavirus (immunology) |
| 59 | Adolescent (MeSH) |
| 57 | Betacoronavirus (genetics) |
| 56 | Young Adult (MeSH) |
| 55 | Severity of Illness Index (MeSH) |
| 54 | Coronavirus (MeSH) |
| 54 | Betacoronavirus (drug effects) |
| 52 | Treatment Outcome (MeSH) |
| 52 | Pneumonia, Viral (physiopathology) |
| 52 | Coronavirus Infections (physiopathology) |
| 49 | Comorbidity (MeSH) |
| 45 | Betacoronavirus (physiology) |
| 43 | Intensive Care Units (MeSH) |
| 43 | Disease Outbreaks (MeSH) |
| 42 | Pneumonia, Viral (pathology) |
| 42 | Coronavirus Infections (pathology) |
| 41 | Time Factors (MeSH) |
| 40 | Tomography, X-Ray Computed (MeSH) |
| 39 | Europe (MeSH) |
| 39 | Clinical Laboratory Techniques (MeSH) |
| 38 | Risk Assessment (MeSH) |
| 38 | Pneumonia, Viral (diagnostic imaging) |
| 38 | Hydroxychloroquine (therapeutic use) |
| 38 | Coronavirus Infections (diagnostic imaging) |
| 36 | Prospective Studies (MeSH) |
| 36 | Pregnancy (MeSH) |
| 35 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
| 35 | Infection Control (methods) |
| 34 | Societies, Medical (MeSH) |
| 34 | Europe (epidemiology) |
| 34 | Age Factors (MeSH) |
| 33 | Global Health (MeSH) |
| 33 | Coronavirus Infections (psychology) |
| 33 | Child, Preschool (MeSH) |
| 32 | Pneumonia, Viral (psychology) |
| 32 | Pneumonia, Viral (blood) |
| 32 | Disease Management (MeSH) |
| 32 | Coronavirus Infections (blood) |
| 30 | Quarantine (MeSH) |
| 29 | Infant (MeSH) |
| 29 | China (MeSH) |
| 27 | Surveys and Questionnaires (MeSH) |
| 27 | Prognosis (MeSH) |
| 27 | Peptidyl-Dipeptidase A (metabolism) |
| 27 | Hospitalization (MeSH) |
| 27 | China (epidemiology) |
| 26 | Infant, Newborn (MeSH) |
| 26 | Incidence (MeSH) |
| 25 | SARS Virus (MeSH) |
| 25 | Pneumonia, Viral (metabolism) |
| 25 | Critical Illness (MeSH) |
| 25 | Coronavirus Infections (metabolism) |
| 24 | Infection Control (standards) |
| 24 | Clinical Laboratory Techniques (methods) |
| 23 | Personal Protective Equipment (MeSH) |
| 23 | Cohort Studies (MeSH) |
| 22 | Lung (diagnostic imaging) |
| 22 | Disease Progression (MeSH) |
| 21 | Prevalence (MeSH) |
| 20 | Telemedicine (MeSH) |
| 20 | Sensitivity and Specificity (MeSH) |
| 20 | Public Health (MeSH) |
| 20 | Italy (MeSH) |
| 20 | Emergencies (MeSH) |
| 20 | Drug Therapy, Combination (MeSH) |
| 20 | Antiviral Agents (pharmacology) |
| 19 | Respiratory Distress Syndrome, Adult (therapy) |
| 19 | Respiration, Artificial (MeSH) |
| 19 | Consensus (MeSH) |
| 19 | Azithromycin (therapeutic use) |
| 18 | Neoplasms (therapy) |
| 18 | Anticoagulants (therapeutic use) |
| 17 | United States (epidemiology) |
| 17 | Risk (MeSH) |
| 17 | Hospitalization (statistics & numerical data) |
| 16 | Triage (MeSH) |
| 16 | Travel (MeSH) |
| 16 | Italy (epidemiology) |
| 16 | Hydroxychloroquine (administration & dosage) |
| 16 | Diagnosis, Differential (MeSH) |
| 16 | Critical Care (MeSH) |
| 16 | Antiviral Agents (adverse effects) |
| 15 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
| 15 | Pandemics (statistics & numerical data) |
| 15 | Nasopharynx (virology) |
| 15 | Delivery of Health Care (MeSH) |
| 14 | Paris (MeSH) |
| 14 | Neoplasms (complications) |
| 14 | Infection Control (MeSH) |
| 14 | Hydroxychloroquine (adverse effects) |
| 13 | Vero Cells (MeSH) |
| 13 | Social Isolation (MeSH) |
| 13 | Respiratory Distress Syndrome, Adult (virology) |
| 13 | Patient Selection (MeSH) |
| 13 | Lung (pathology) |
| 13 | Host-Pathogen Interactions (MeSH) |
| 13 | Health Personnel (MeSH) |
| 13 | Drug Repositioning (MeSH) |
| 13 | Disease Transmission, Infectious (prevention & control) |
| 13 | Delivery of Health Care (organization & administration) |
| 13 | Cross-Sectional Studies (MeSH) |
| 13 | Chlorocebus aethiops (MeSH) |
| 12 | Time-to-Treatment (MeSH) |
| 12 | Registries (MeSH) |
| 12 | Models, Statistical (MeSH) |
| 12 | Magnetic Resonance Imaging (MeSH) |
| 12 | Intensive Care Units (statistics & numerical data) |
| 12 | Intensive Care Units (organization & administration) |
| 12 | Immunologic Factors (therapeutic use) |
| 12 | Clinical Trials as Topic (MeSH) |
| 12 | Anti-Bacterial Agents (therapeutic use) |
| 12 | Algorithms (MeSH) |
| 12 | Alanine (analogs & derivatives) |
| 12 | Adenosine Monophosphate (analogs & derivatives) |
| 12 | Acute Disease (MeSH) |
| 11 | Viral Load (MeSH) |
| 11 | United States (MeSH) |
| 11 | Telemedicine (methods) |
| 11 | RNA, Viral (genetics) |
| 11 | Population Surveillance (MeSH) |
| 11 | Paris (epidemiology) |
| 11 | Immunocompromised Host (MeSH) |
| 11 | Health Services Accessibility (MeSH) |
| 11 | Fibrin Fibrinogen Degradation Products (analysis) |
| 11 | Disease Outbreaks (prevention & control) |
| 11 | Cross Infection (prevention & control) |
| 11 | Communicable Disease Control (methods) |
| 11 | Communicable Disease Control (MeSH) |
| 11 | Betacoronavirus (metabolism) |
| 10 | World Health Organization (MeSH) |
| 10 | Virus Replication (drug effects) |
| 10 | Spain (epidemiology) |
| 10 | Severe Acute Respiratory Syndrome (virology) |
| 10 | Severe Acute Respiratory Syndrome (epidemiology) |
| 10 | Respiratory Distress Syndrome, Adult (etiology) |
| 10 | Real-Time Polymerase Chain Reaction (MeSH) |
| 10 | Randomized Controlled Trials as Topic (MeSH) |
| 10 | International Cooperation (MeSH) |
| 10 | Inflammation (MeSH) |
| 10 | Hydroxychloroquine (pharmacology) |
| 10 | Extracorporeal Membrane Oxygenation (MeSH) |
| 10 | Epidemics (MeSH) |
| 10 | Drug Interactions (MeSH) |
| 10 | Critical Care (methods) |
| 10 | Clinical Decision-Making (MeSH) |
| 10 | Chloroquine (therapeutic use) |
| 10 | Case-Control Studies (MeSH) |
| 10 | Biomarkers (blood) |
| 10 | Antibodies, Viral (blood) |
| 10 | Aerosols (MeSH) |
| 10 | Adrenal Cortex Hormones (therapeutic use) |
| 9 | Vulnerable Populations (MeSH) |
| 9 | Symptom Assessment (MeSH) |
| 9 | Survival Analysis (MeSH) |
| 9 | Pulmonary Embolism (virology) |
| 9 | Pregnancy Complications, Infectious (virology) |
| 9 | Pneumonia, Viral (etiology) |
| 9 | Pneumonia, Viral (economics) |
| 9 | Phylogeny (MeSH) |
| 9 | Patient Safety (MeSH) |
| 9 | Patient Isolation (MeSH) |
| 9 | Patient Care Team (MeSH) |
| 9 | Pandemics (economics) |
| 9 | Models, Biological (MeSH) |
| 9 | Mental Disorders (epidemiology) |
| 9 | Masks (MeSH) |
| 9 | Internationality (MeSH) |
| 9 | Hydroxychloroquine (MeSH) |
| 9 | Genome, Viral (MeSH) |
| 9 | Follow-Up Studies (MeSH) |
| 9 | Delivery of Health Care (methods) |
| 9 | Cytokine Release Syndrome (etiology) |
| 9 | Coronavirus Infections (genetics) |
| 9 | Coronavirus Infections (economics) |
| 9 | Coronavirus (isolation & purification) |
| 9 | Betacoronavirus (chemistry) |
| 9 | Antiviral Agents (administration & dosage) |
| 9 | Antimalarials (therapeutic use) |
| 9 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 8 | Withholding Treatment (MeSH) |
| 8 | Thrombophilia (etiology) |
| 8 | Spike Glycoprotein, Coronavirus (metabolism) |
| 8 | Spike Glycoprotein, Coronavirus (chemistry) |
| 8 | Renin-Angiotensin System (physiology) |
| 8 | Radiography, Thoracic (MeSH) |
| 8 | Quarantine (psychology) |
| 8 | Pulmonary Embolism (epidemiology) |
| 8 | Prone Position (MeSH) |
| 8 | Pregnancy Complications, Infectious (therapy) |
| 8 | Polymerase Chain Reaction (MeSH) |
| 8 | Phenotype (MeSH) |
| 8 | Olfaction Disorders (etiology) |
| 8 | Occupational Diseases (prevention & control) |
| 8 | Models, Theoretical (MeSH) |
| 8 | Mice (MeSH) |
| 8 | Mental Health (MeSH) |
| 8 | Medical Oncology (standards) |
| 8 | Medical Oncology (organization & administration) |
| 8 | Lung (virology) |
| 8 | Internet (MeSH) |
| 8 | Infection Control (organization & administration) |
| 8 | Health Care Surveys (MeSH) |
| 8 | Equipment Design (MeSH) |
| 8 | Adaptation, Psychological (MeSH) |
| 7 | Venous Thromboembolism (prevention & control) |
| 7 | United Kingdom (epidemiology) |
| 7 | Ultrasonography (MeSH) |
| 7 | Tracheostomy (methods) |
| 7 | Stroke (therapy) |
| 7 | Spike Glycoprotein, Coronavirus (genetics) |
| 7 | Socioeconomic Factors (MeSH) |
| 7 | Sex Factors (MeSH) |
| 7 | Severe Acute Respiratory Syndrome (immunology) |
| 7 | Seasons (MeSH) |
| 7 | Respiratory Distress Syndrome, Adult (MeSH) |
| 7 | RNA, Viral (analysis) |
| 7 | Pregnancy Complications, Infectious (diagnosis) |
| 7 | Pneumonia, Viral (genetics) |
| 7 | Outcome Assessment, Health Care (MeSH) |
| 7 | Olfaction Disorders (virology) |
| 7 | Olfaction Disorders (epidemiology) |
| 7 | Occupational Health (MeSH) |
| 7 | Nursing Homes (MeSH) |
| 7 | Neoplasms (epidemiology) |
| 7 | Neoplasms (drug therapy) |
| 7 | Mortality (MeSH) |
| 7 | Models, Molecular (MeSH) |
| 7 | Mental Disorders (therapy) |
| 7 | Length of Stay (MeSH) |
| 7 | Interdisciplinary Communication (MeSH) |
| 7 | Infectious Disease Transmission, Professional-to-Patient (prevention & control) |
| 7 | Immunosuppressive Agents (therapeutic use) |
| 7 | Immunoglobulins, Intravenous (therapeutic use) |
| 7 | Immunity, Innate (MeSH) |
| 7 | Hospital Units (organization & administration) |
| 7 | Guidelines as Topic (MeSH) |
| 7 | Glucocorticoids (therapeutic use) |
| 7 | Drug Combinations (MeSH) |
| 7 | Decision Making (MeSH) |
| 7 | Critical Care (standards) |
| 7 | Communication (MeSH) |
| 7 | Coinfection (MeSH) |
| 7 | Chloroquine (adverse effects) |
| 7 | Cardiovascular Diseases (epidemiology) |
| 7 | Antiviral Agents (pharmacokinetics) |
| 7 | Alanine (therapeutic use) |
| 7 | Adenosine Monophosphate (therapeutic use) |
| 6 | Viral Nonstructural Proteins (genetics) |
| 6 | Survival Rate (MeSH) |
| 6 | Stress, Psychological (etiology) |
| 6 | Spain (MeSH) |
| 6 | Software (MeSH) |
| 6 | Social Isolation (psychology) |
| 6 | Severe Acute Respiratory Syndrome (MeSH) |
| 6 | Respiration, Artificial (statistics & numerical data) |
| 6 | Respiration, Artificial (methods) |
| 6 | Radiography, Thoracic (methods) |
| 6 | Pulmonary Embolism (diagnostic imaging) |
| 6 | Pulmonary Embolism (diagnosis) |
| 6 | Pulmonary Embolism (complications) |
| 6 | Pregnancy Complications, Infectious (epidemiology) |
| 6 | Peptidyl-Dipeptidase A (genetics) |
| 6 | Peptidyl-Dipeptidase A (MeSH) |
| 6 | Operating Rooms (organization & administration) |
| 6 | Occupational Exposure (prevention & control) |
| 6 | Mutation (MeSH) |
| 6 | Medical Oncology (MeSH) |
| 6 | Mass Screening (MeSH) |
| 6 | Iran (epidemiology) |
| 6 | Intensive Care Units (supply & distribution) |
| 6 | Hypoxia (etiology) |
| 6 | Hospital Mortality (MeSH) |
| 6 | Health Services Needs and Demand (MeSH) |
| 6 | Health Behavior (MeSH) |
| 6 | Genome, Viral (genetics) |
| 6 | Forecasting (MeSH) |
| 6 | Fatal Outcome (MeSH) |
| 6 | Exercise (MeSH) |
| 6 | Emergency Service, Hospital (organization & administration) |
| 6 | Electrocardiography (MeSH) |
| 6 | Elective Surgical Procedures (MeSH) |
| 6 | Drug Synergism (MeSH) |
| 6 | Disinfection (MeSH) |
| 6 | Digestive System Surgical Procedures (MeSH) |
| 6 | Cytokines (immunology) |
| 6 | Coronavirus Infections (etiology) |
| 6 | Coronavirus (classification) |
| 6 | Computer Simulation (MeSH) |
| 6 | Computed Tomography Angiography (MeSH) |
| 6 | Chronic Disease (MeSH) |
| 6 | Chloroquine (administration & dosage) |
| 6 | Cardiovascular Diseases (complications) |
| 6 | Brain Ischemia (therapy) |
| 6 | Basic Reproduction Number (MeSH) |
| 6 | Azithromycin (adverse effects) |
| 6 | Azithromycin (administration & dosage) |
| 6 | Azithromycin (MeSH) |
| 6 | Attitude of Health Personnel (MeSH) |
| 6 | Antibodies, Viral (immunology) |
| 6 | Antibodies, Neutralizing (immunology) |
| 6 | Anti-Inflammatory Agents (therapeutic use) |
| 6 | Angiotensin-Converting Enzyme Inhibitors (therapeutic use) |
| 6 | Amino Acid Sequence (MeSH) |
| 6 | Ambulatory Care (MeSH) |
| 5 | Zoonoses (virology) |
| 5 | Zoonoses (MeSH) |
| 5 | Virus Replication (physiology) |
| 5 | Virulence (MeSH) |
| 5 | Viral Vaccines (MeSH) |
| 5 | Viral Proteins (genetics) |
| 5 | Viral Nonstructural Proteins (metabolism) |
| 5 | Viral Load (drug effects) |
| 5 | Thrombosis (etiology) |
| 5 | Thrombophilia (drug therapy) |
| 5 | Thrombophilia (blood) |
| 5 | Telemedicine (trends) |
| 5 | Telemedicine (statistics & numerical data) |
| 5 | Telemedicine (organization & administration) |
| 5 | Taste (MeSH) |
| 5 | Structure-Activity Relationship (MeSH) |
| 5 | Stress Disorders, Post-Traumatic (etiology) |
| 5 | Spike Glycoprotein, Coronavirus (immunology) |
| 5 | Smell (MeSH) |
| 5 | Serologic Tests (methods) |
| 5 | SARS Virus (genetics) |
| 5 | Respiratory Insufficiency (drug therapy) |
| 5 | Republic of Korea (epidemiology) |
| 5 | Renin-Angiotensin System (drug effects) |
| 5 | RNA, Viral (isolation & purification) |
| 5 | Quarantine (methods) |
| 5 | Protective Devices (MeSH) |
| 5 | Procedures and Techniques Utilization (MeSH) |
| 5 | Pregnant Women (MeSH) |
| 5 | Predictive Value of Tests (MeSH) |
| 5 | Practice Patterns, Physicians' (statistics & numerical data) |
| 5 | Point-of-Care Testing (MeSH) |
| 5 | Pilot Projects (MeSH) |
| 5 | Personal Protective Equipment (standards) |
| 5 | Patient Positioning (MeSH) |
| 5 | Otolaryngology (standards) |
| 5 | Otolaryngology (MeSH) |
| 5 | Olfaction Disorders (physiopathology) |
| 5 | Obesity (complications) |
| 5 | Neoplasms (radiotherapy) |
| 5 | Middle East Respiratory Syndrome Coronavirus (MeSH) |
| 5 | Mental Health Services (organization & administration) |
| 5 | Lymphopenia (etiology) |
| 5 | Long QT Syndrome (chemically induced) |
| 5 | Kidney Transplantation (MeSH) |
| 5 | Inpatients (MeSH) |
| 5 | Influenza, Human (epidemiology) |
| 5 | Infectious Disease Transmission, Vertical (prevention & control) |
| 5 | Infectious Disease Transmission, Vertical (MeSH) |
| 5 | Immunosuppressive Agents (adverse effects) |
| 5 | Immunoglobulin G (blood) |
| 5 | Immunity, Innate (drug effects) |
| 5 | Hypoglycemic Agents (therapeutic use) |
| 5 | Hygiene (MeSH) |
| 5 | Hospitals, University (MeSH) |
| 5 | History, 21st Century (MeSH) |
| 5 | Health Resources (supply & distribution) |
| 5 | Health Priorities (MeSH) |
| 5 | Health Personnel (statistics & numerical data) |
| 5 | Fibrin Fibrinogen Degradation Products (metabolism) |
| 5 | Feasibility Studies (MeSH) |
| 5 | Evolution, Molecular (MeSH) |
| 5 | Evidence-Based Medicine (MeSH) |
| 5 | Emergency Service, Hospital (MeSH) |
| 5 | Early Diagnosis (MeSH) |
| 5 | Drug Monitoring (MeSH) |
| 5 | Drug Administration Schedule (MeSH) |
| 5 | Dose-Response Relationship, Drug (MeSH) |
| 5 | Cytokines (metabolism) |
| 5 | Cytokines (antagonists & inhibitors) |
| 5 | Cytokine Release Syndrome (drug therapy) |
| 5 | Cross Infection (transmission) |
| 5 | Critical Care (organization & administration) |
| 5 | Coronavirus (genetics) |
| 5 | Contraindications, Drug (MeSH) |
| 5 | Continuity of Patient Care (organization & administration) |
| 5 | Contact Tracing (MeSH) |
| 5 | Communicable Diseases, Emerging (epidemiology) |
| 5 | Clinical Trials as Topic (standards) |
| 5 | Chilblains (diagnosis) |
| 5 | Blood Coagulation (MeSH) |
| 5 | Biomedical Research (organization & administration) |
| 5 | Biomarkers (MeSH) |
| 5 | Betacoronavirus (ultrastructure) |
| 5 | Betacoronavirus (classification) |
| 5 | Bed Conversion (MeSH) |
| 5 | Azithromycin (pharmacology) |
| 5 | Attitude to Health (MeSH) |
| 5 | Asymptomatic Diseases (MeSH) |
| 5 | Anxiety (psychology) |
| 5 | Antiviral Agents (chemistry) |
| 5 | Antineoplastic Agents (therapeutic use) |
| 5 | Air Pollution (MeSH) |
| 5 | Air Microbiology (MeSH) |
| 5 | Age Distribution (MeSH) |
| 5 | Africa (epidemiology) |
| 4 | Virus Internalization (drug effects) |
| 4 | Virus Internalization (MeSH) |
| 4 | Viral Vaccines (therapeutic use) |
| 4 | Viral Vaccines (immunology) |
| 4 | Viral Tropism (MeSH) |
| 4 | Viral Envelope Proteins (genetics) |
| 4 | Venous Thrombosis (virology) |
| 4 | Venous Thromboembolism (virology) |
| 4 | Venous Thromboembolism (etiology) |
| 4 | Venous Thromboembolism (epidemiology) |
| 4 | Venous Thromboembolism (blood) |
| 4 | Vaccination (MeSH) |
| 4 | Urology (organization & administration) |
| 4 | Urology (methods) |
| 4 | Urologic Diseases (therapy) |
| 4 | Urologic Diseases (diagnosis) |
| 4 | Triage (organization & administration) |
| 4 | Triage (methods) |
| 4 | Treatment Failure (MeSH) |
| 4 | Thrombosis (virology) |
| 4 | Thrombosis (MeSH) |
| 4 | Systemic Inflammatory Response Syndrome (epidemiology) |
| 4 | Survival Rate (trends) |
| 4 | Surgical Oncology (standards) |
| 4 | Stroke (etiology) |
| 4 | Stroke (diagnostic imaging) |
| 4 | Standard of Care (MeSH) |
| 4 | Societies, Medical (standards) |
| 4 | Social Distance (MeSH) |
| 4 | Sex Distribution (MeSH) |
| 4 | Severe Acute Respiratory Syndrome (drug therapy) |
| 4 | Severe Acute Respiratory Syndrome (diagnosis) |
| 4 | Seroepidemiologic Studies (MeSH) |
| 4 | Sequence Alignment (MeSH) |
| 4 | ST Elevation Myocardial Infarction (therapy) |
| 4 | Ritonavir (administration & dosage) |
| 4 | Reverse Transcriptase Polymerase Chain Reaction (methods) |
| 4 | Respiratory Distress Syndrome, Adult (physiopathology) |
| 4 | Respiratory Distress Syndrome, Adult (epidemiology) |
| 4 | Respiratory Distress Syndrome, Adult (drug therapy) |
| 4 | Respiration, Artificial (adverse effects) |
| 4 | Research Design (MeSH) |
| 4 | Reproducibility of Results (MeSH) |
| 4 | Renin-Angiotensin System (MeSH) |
| 4 | Renal Dialysis (MeSH) |
| 4 | Registries (statistics & numerical data) |
| 4 | Quarantine (statistics & numerical data) |
| 4 | Pulmonary Embolism (etiology) |
| 4 | Public Opinion (MeSH) |
| 4 | Psychotropic Drugs (therapeutic use) |
| 4 | Preoperative Care (MeSH) |
| 4 | Positron Emission Tomography Computed Tomography (MeSH) |
| 4 | Pneumonia, Viral (surgery) |
| 4 | Pneumonia, Viral (rehabilitation) |
| 4 | Pneumonia (MeSH) |
| 4 | Placenta (virology) |
| 4 | Pediatrics (methods) |
| 4 | Patient Positioning (methods) |
